Indication · Parkinsons Disease (PD)

Parkinsons Disease (PD) FDA approvals, PDUFA dates and pipeline.

Updated Snapshot 20261116T222116ZBuilt

We track 3 Parkinsons Disease (PD) drugs. No FDA approvals recorded yet.

Drugs

DrugSponsorModalityDesignations
bezisterim (NE3107)BIVI——
buntanetap/posiphenANVS——
foscarbidopa (ABBV-951)ABBV——

Upcoming catalysts

No events in this view.

Past catalysts and decisions

DateDrugCompanyEventIndicationStatusSource
May 1, 2026bezisterim (NE3107)BIVIPrimary completionParkinsons Disease (PD)CompletedClinicalTrials.gov
April 27, 2026foscarbidopa (ABBV-951)ABBVPrimary completionParkinson's Disease (PD)CompletedClinicalTrials.gov
April 17, 2026foscarbidopa (ABBV-951)ABBVPrimary completionParkinson's Disease (PD)CompletedClinicalTrials.gov

All indications · Approval rates by indication

Questions

What Parkinsons Disease (PD) drugs have upcoming PDUFA dates?

None disclosed.

Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.